Technical Analysis for TAK - Takeda Pharmaceutical Company Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 13.16 | 0.08% | 0.01 |
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Cup with Handle | Other | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | 0.08% | |
NR7 | Range Contraction | 0.08% | |
NR7-2 | Range Contraction | 0.08% | |
Narrow Range Bar | Range Contraction | 0.08% | |
New 52 Week Low | Weakness | 0.08% | |
Gapped Down | Weakness | 0.08% | |
Oversold Stochastic | Weakness | 0.08% | |
NR7 | Range Contraction | -0.53% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 16 hours ago |
Possible NR7 | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
New 52 Week Low | 1 day ago |
Possible NR7 | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Takeda Pharmaceutical Company Limited Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Immunology Pharmacy Pharmaceutical Products Rare Diseases Hematology Healthcare Products Gastroenterology Specialty Drugs Cancer Center Nasdaq Biotechnology Index Arcturus Therapeutics Novimmune University Of Texas Md Anderson Cancer Center
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.115 |
52 Week Low | 13.11 |
Average Volume | 1,698,423 |
200-Day Moving Average | 14.65 |
50-Day Moving Average | 14.19 |
20-Day Moving Average | 13.69 |
10-Day Moving Average | 13.42 |
Average True Range | 0.17 |
RSI (14) | 29.08 |
ADX | 34.89 |
+DI | 14.51 |
-DI | 42.68 |
Chandelier Exit (Long, 3 ATRs) | 14.03 |
Chandelier Exit (Short, 3 ATRs) | 13.63 |
Upper Bollinger Bands | 14.49 |
Lower Bollinger Band | 12.89 |
Percent B (%b) | 0.17 |
BandWidth | 11.74 |
MACD Line | -0.31 |
MACD Signal Line | -0.27 |
MACD Histogram | -0.0389 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.32 | ||||
Resistance 3 (R3) | 13.32 | 13.27 | 13.29 | ||
Resistance 2 (R2) | 13.27 | 13.23 | 13.27 | 13.28 | |
Resistance 1 (R1) | 13.22 | 13.21 | 13.21 | 13.21 | 13.27 |
Pivot Point | 13.17 | 13.17 | 13.17 | 13.17 | 13.17 |
Support 1 (S1) | 13.11 | 13.13 | 13.11 | 13.11 | 13.05 |
Support 2 (S2) | 13.06 | 13.10 | 13.06 | 13.04 | |
Support 3 (S3) | 13.01 | 13.06 | 13.03 | ||
Support 4 (S4) | 13.00 |